Researchers are one step closer to the drug to treat Ebola virus, after a new treatment was used to save contaminated monkeys. They have now approved to do the clinical trials on a small group of human participants. Ebola virus causes fatality in ninety percent of individual cases but is always lethal to apes.
Ebola virus transmitted through body fluids. Sufferer experiences nausea, vomiting, and internal bleeding and organ failure before patient die. Approximately more than one thousand people have died from the disease since it was discovered in 1976. There are fears that it could be used as bio-weapon by terrorists.
Nevertheless two untried treatments have shown big assurance. Those have protected sixty percent monkeys contaminated with Ebola virus and the monkeys contaminated with a correlated virus known as Marburg. The study author Sina Bavari and team used antisense therapies to stop the virus, reported the study published in the journal Nature Medicine.
The small elongation of hereditary matter blocked the deed of a precise gene and prevent Ebola virus from spreading. It provided the immune system time to take over. The drug is being developed by the US Army Medical Research Institute of Infectious Diseases and the private company AVI BioPharma.
Ebola transmits through close personal contacts and depending on the sprain can kill up to ninety percent of victims. Researcher explained that taken collectively both the studies give a chief development in therapeutic field in efforts for treating filovirus hemorrhagic fever.